CLINICAL_TRIALS ClinicalTrials.gov record update

Brentuximab Vedotin (ADCETRIS) IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma"

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02139592
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:37:39.196355+00:00
Published At: 2019-05-06T00:00:00+00:00
Record Updated At: 2020-07-13
Results Posted At: 2019-05-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Relapsed or Refractory CD30+ Hodgkin\u0027s Lymphoma or Anaplastic Large Cell Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2020-07-13"
protocolSection.identificationModule.nctId: "NCT02139592"
protocolSection.identificationModule.officialTitle: "Brentuximab Vedotin (ADCETRIS) IV Infusion - Special Drug Use Surveillance (All-case Surveillance) \"Relapsed or Refractory CD30+ Hodgkin\u0027s Lymphoma or Anaplastic Large Cell Lymphoma\""
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: []
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2019-05-06"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.